Bionoid Competitors

Pink Sheets . USA . 
Stock . Bionoid Pharma
BINP Stock  USD 0.11  0.09  45.00%   
Bionoid Pharma competes with Smith Douglas, United Homes, JBG SMITH, Treasury Wine, and MI Homes; as well as few others. The company conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Bionoid Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bionoid Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Bionoid Pharma Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bionoid Pharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.1113.61
Details
Intrinsic
Valuation
LowRealHigh
0.010.1113.61
Details

Bionoid Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bionoid Pharma and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Bionoid and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bionoid Pharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
DWWEF
+ 1.0
MAHN
JBGS
+ 0.73
SDHC
MHO
+ 0.7
SDHC
MHO
+ 0.57
JBGS
TSRYF
+ 0.36
SDHC
TSRYF
+ 0.23
JBGS
  
High negative correlations   
JBGS
- 0.52
UHG
UHG
- 0.19
SDHC
TSRYF
- 0.11
UHG
MHO
- 0.1
TSRYF
DWWEF
- 0.0
MHO
DWWEF
- 0.0
TSRYF

Risk-Adjusted Indicators

There is a big difference between Bionoid Pink Sheet performing well and Bionoid Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bionoid Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Bionoid Pharma Competitive Analysis

The better you understand Bionoid Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bionoid Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bionoid Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BINP SDHC UHG MAHN JBGS TSRYF MHO DWWEF
 45.00 
 0.11 
Bionoid
 1.18 
 32.75 
Smith
 4.27 
 6.11 
United
 0.00 
 0.0001 
Mid-Atlantic
 0.36 
 16.73 
JBG
 9.87 
 6.85 
Treasury
 2.38 
 165.12 
MHO
 0.00 
 0.16 
Diamond
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Moderately volatile
Very steady
Very steady
Somewhat reliable
Very steady
Very steady
Market Performance
(90 Days Performance)
Weak
Very Weak
Weak
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Quite High
Low
Below Average
Low
Below Average
Low
Very Low
Quite High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Strong Sell
Not Available
Hold
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Hold
Hold
Strong Sell
Strong Hold
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
0.07 X
N/A
N/A
1.17 X
4.68 X
1.98 X
6.73 X
3.50 X
Net Asset
N/A
352.69 M
298.65 M
8.89 M
5.52 B
6.66 B
4.02 B
68.17 M
Profit Margin
N/A
0.16 %
(0.05) %
0 %
(0.20) %
0.10 %
0.13 %
(0.13) %
EBITDA
(385.71 K)
124.97 M
15.96 M
939.29 K
242.89 M
644.4 M
591.36 M
(180.5 K)
Operating Margin
(4.22) %
0.14 %
0.04 %
0.03 %
0.05 %
0.20 %
0.16 %
(0.15) %
Current Valuation
3.81 M
1.69 B
402.22 M
3.91 M
3.94 B
7.55 B
4.64 B
34.85 M
Price To Book
N/A
24.83 X
14.33 X
N/A
0.74 X
2.59 X
1.54 X
1.10 X
Retained Earnings
N/A
N/A
(33.98 M)
1.88 M
(776.96 M)
78 M
2.3 B
N/A
Current Asset
N/A
N/A
N/A
6.4 M
340.89 M
1.87 B
1.13 B
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
1.84 %
0.71 %
N/A
Beta
-2.12
N/A
0.61
1.64
1.08
0.44
2.24
1.33
Number Of Employees
5
364
N/A
1.25 K
844
2.5 K
1.61 K
6
Shares Outstanding
42.28 M
8.85 M
11.44 M
12.06 M
84.48 M
721.85 M
27.21 M
27.88 M
Cash Flow From Operations
(357.62 K)
76.26 M
28.22 M
1.28 M
183.37 M
562 M
552.13 M
(2.33 M)
Annual Yield
N/A
N/A
N/A
N/A
0.04 %
0.02 %
N/A
N/A
Total Debt
64.5 K
78.4 M
154.06 M
401.76 K
2.64 B
1.51 B
917.15 M
28.68 M
Return On Equity
N/A
0.7
-0.75
0.0123
-0.0557
0.0713
0.2
-0.18
Z Score
N/A
N/A
N/A
3.0
N/A
2.4
N/A
0.6
Return On Asset
-1.64
N/A
0.0193
0.0608
0.002
0.0496
0.0973
-0.0531
Book Value Per Share
(29.92) X
N/A
0.41 X
0.18 X
22.29 X
5.24 X
104.59 X
0.99 X
Number Of Shares Shorted
N/A
204.69 K
221.88 K
N/A
6.44 M
N/A
1.02 M
N/A
Current Liabilities
N/A
N/A
N/A
5.46 M
174.69 M
758 M
106.44 M
N/A
Total Asset
N/A
352.69 M
298.65 M
8.89 M
5.52 B
6.66 B
4.02 B
68.17 M
Short Ratio
N/A
1.45 X
9.22 X
N/A
15.49 X
N/A
4.31 X
N/A
Target Price
N/A
27.0
N/A
N/A
17.0
N/A
197.5
N/A
Debt To Equity
N/A
N/A
N/A
2.06 %
0.60 %
0.44 %
0.48 %
0.86 %
Last Dividend Paid
N/A
N/A
N/A
N/A
0.7
0.31
N/A
N/A
Shares Owned By Institutions
N/A
35.20 %
30.75 %
N/A
93.79 %
42.30 %
97.70 %
1.50 %
Market Capitalization
42.28 M
1.61 B
283.68 M
2.41 K
1.41 B
7.21 B
4.6 B
29.25 M
Price To Earning
N/A
N/A
N/A
7.00 X
297.26 X
50.27 X
4.41 X
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
4.80 X
N/A
0.78 X
N/A
Price To Sales
540.76 X
1.88 X
0.64 X
0.01 X
2.48 X
2.59 X
1.08 X
0.91 X
Net Income
(1.62 M)
123.18 M
125.06 M
(35.2 K)
(91.71 M)
263.2 M
465.37 M
(2.47 M)
Earnings Per Share
(46.27) X
N/A
(0.59) X
0 X
(1.28) X
0.25 X
18.61 X
(0.03) X
Shares Owned By Insiders
N/A
3.69 %
43.47 %
N/A
0.03 %
0.29 %
2.30 %
36.36 %
Revenue
92.26 K
764.63 M
421.47 M
28.34 M
604.2 M
2.48 B
4.03 B
29.99 M
Working Capital
N/A
260.62 M
151.9 M
937 K
242.61 M
1.11 B
3.42 B
N/A
Cash And Equivalents
127
N/A
N/A
750.28 K
162.27 M
430.5 M
311.54 M
N/A
Cash Per Share
N/A
N/A
N/A
0.06 X
1.42 X
0.60 X
2.43 X
N/A
Gross Profit
47.48 K
N/A
N/A
6.31 M
301 M
1.07 B
1.06 B
11.05 M
Day Typical Price
0.11
32.53
6.07
1.0E-4
16.68
6.85
165.3
0.16
Accumulation Distribution
N/A
1375.04
2135.38
N/A
9009.83
N/A
9462.32
N/A
Daily Balance Of Power
(9,223,372,036,855)
(0.29)
0.4098
0.0
0.1875
(9,223,372,036,855)
(0.68)
0.0
Period Momentum Indicator
(0.09)
(0.39)
0.25
N/A
0.06
(0.75)
(4.02)
N/A
Rate Of Daily Change
0.55
0.99
1.04
1.0
1.0
0.9
0.98
1.0
Day Median Price
0.11
32.42
6.06
1.0E-4
16.66
6.85
165.39
0.16
Price Action Indicator
(0.04)
0.13
0.18
N/A
0.1
(0.37)
(2.27)
N/A
Coefficient Of Variation
1868.43
(3,116)
(13,161)
N/A
(3,383)
(995.86)
2963.45
N/A
Mean Deviation
5.39
2.4
2.99
N/A
1.14
1.0
1.67
N/A
Jensen Alpha
0.7733
(0.22)
(0.25)
N/A
(0.17)
(0.21)
(0.07)
N/A
Total Risk Alpha
(1.36)
(0.60)
(0.64)
N/A
(0.32)
(0.59)
(0.28)
N/A
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
(0.02)
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
5.98
N/A
Standard Deviation
13.28
3.15
3.87
N/A
1.69
2.25
2.24
N/A
Kurtosis
9.96
(0.01)
0.4689
N/A
4.49
8.54
0.6753
N/A
Potential Upside
25.0
6.08
7.79
N/A
2.58
1.71
3.69
N/A
Treynor Ratio
(1.15)
(0.12)
(0.02)
N/A
(0.06)
1.07
0.0566
N/A
Maximum Drawdown
85.0
13.47
17.32
N/A
9.14
18.03
10.66
N/A
Variance
176.44
9.92
14.97
N/A
2.85
5.08
5.01
N/A
Market Risk Adjusted Performance
(1.14)
(0.11)
(0.01)
N/A
(0.05)
1.08
0.0666
N/A
Risk Adjusted Performance
0.0503
(0.02)
0.0022
N/A
(0.02)
(0.07)
0.0324
N/A
Skewness
(0.75)
0.0735
0.4742
N/A
(0.21)
(0.76)
(0.32)
N/A
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
2.39
N/A
Information Ratio
0.0438
(0.07)
(0.04)
N/A
(0.11)
(0.16)
(0.02)
N/A
Value At Risk
(10.00)
(5.92)
(6.00)
N/A
(2.38)
(5.10)
(4.24)
N/A
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
(1.61)
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
2.45
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
5.7
N/A

Bionoid Pharma Competition Performance Charts

Five steps to successful analysis of Bionoid Pharma Competition

Bionoid Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bionoid Pharma in relation to its competition. Bionoid Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Bionoid Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bionoid Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bionoid Pharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Bionoid Pharma position

In addition to having Bionoid Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Pharmaceutical Products Thematic Idea Now

Pharmaceutical Products
Pharmaceutical Products Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Pharmaceutical Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Pharmaceutical Products Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Bionoid Pink Sheet Analysis

When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY